XML 159 R135.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condended Financial Information of Registrant Statements of Cash Flow (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Cash flows from operating activities:                      
Net income (loss) $ 19,005 $ 18,824 $ 7,006 $ 27,786 $ 13,687 $ (27,761) $ (13,088) $ (18,673) $ 72,621 $ (45,835) $ (39,911)
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:                      
Depreciation, depletion, and amortization                 45,989 31,617 19,918
Non-cash interest expense                 7,276 18,121 12,449
Change in value of common stock warrants                 1,674 (2,962) 3,664
Deferred taxes                 (1,321) (7,935) (16,489)
Stock-based compensation                 7,204 6,625 5,165
Equity in losses (income) of subsidiaries                 (18,369) 22,381 55,983
Loss on termination of financing agreements                 8,633 0 19,669
Net changes in operating assets and liabilities:                      
Prepaid and other assets                 37,645 447 (35,697)
Accounts payable and other accrued liabilities                 (33,780) (26,698) (26,188)
Net cash provided by (used in) operating activities                 106,483 (23,891) 132,358
Cash flows from investing activities:                      
Change in restricted cash                 502 0 0
Capital expenditures                 (31,708) (24,833) (22,345)
Net cash used in investing activities                 (31,171) (286,243) (114,205)
Cash flows from financing activities:                      
Proceeds from sale of common stock, net of offering costs                 0 49,044 76,056
Proceeds from borrowings                 616,706 354,682 208,158
Repayments of borrowings                 (603,770) (202,165) (227,212)
Payment of deferred loan costs                 (10,064) (6,892) (7,335)
Other financing activities, net                 (993) (598) (995)
Net cash provided by (used in) financing activities                 (4,751) 190,118 60,425
Net increase (decrease) in cash and cash equivalents                 70,561 (120,016) 78,578
Cash and cash equivalents at beginning of period       47,772       167,788 47,772 167,788 89,210
Cash and cash equivalents at end of period 118,333       47,772       118,333 47,772 167,788
Net cash received (paid) for:                      
Interest                 (23,873) (13,217) (6,891)
Taxes                   (589) (402)
Non-cash investing and financing activities:                      
Accrued capital expenditures                 2,926 4,907 2,102
Value of warrants and debt reclassified to equity                 0 3,084 7,691
Capital lease additions                 165 1,575 216
Parent Company                      
Cash flows from operating activities:                      
Net income (loss)                 72,621 (45,835) (39,911)
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:                      
Depreciation, depletion, and amortization                 2,871 2,205 962
Non-cash interest expense                 5,617 13,722 6,860
Non-cash interest income from subsidiary                 0 (583) (1,000)
Change in value of common stock warrants                 1,674 (2,962) 3,644
Deferred taxes                 0 (8,573) 0
Stock-based compensation                 7,204 2,226 3,202
Equity in losses (income) of subsidiaries                 (111,162) 17,170 5,137
Loss on termination of financing agreements                 1,804 0 0
Net changes in operating assets and liabilities:                      
Prepaid and other assets                 (2,568) 25 (8,466)
Accounts payable and other accrued liabilities                 3,088 381 3,674
Net cash provided by (used in) operating activities                 (18,851) (22,224) (25,898)
Cash flows from investing activities:                      
Investments in subsidiaries                 (2,072) (264,163) (89,603)
Distributions from subsidiaries                 70,645 9,047 68,418
Note receivable from subsidiary                 0 10,000 0
Change in restricted cash                 2 0 0
Capital expenditures                 (5,366) (4,321) (4,461)
Due to (from) subsidiaries                 80,762 (23,947) 27,627
Net cash used in investing activities                 143,971 (273,384) 1,981
Cash flows from financing activities:                      
Proceeds from sale of common stock, net of offering costs                 0 49,044 76,056
Proceeds from borrowings                 0 172,282 7,378
Repayments of borrowings                 (68,873) (63,062) (37,214)
Payment of deferred loan costs                 0 (6,298) (307)
Due to (from) subsidiaries                 0 63,578 0
Other financing activities, net                 (993) (598) (1,087)
Net cash provided by (used in) financing activities                 (69,866) 214,946 44,826
Net increase (decrease) in cash and cash equivalents                 55,254 (80,662) 20,909
Cash and cash equivalents at beginning of period       $ 10,361       $ 91,023 10,361 91,023 70,114
Cash and cash equivalents at end of period $ 65,615       $ 10,361       65,615 10,361 91,023
Net cash received (paid) for:                      
Interest                 (7,856) (4,557) (4,709)
Taxes                 (1,478) 0 51
Non-cash investing and financing activities:                      
Accrued capital expenditures                 370 361 417
Value of warrants and debt reclassified to equity                 0 3,084 7,691
Capital lease additions                 $ 165 $ 1,575 $ 216